Abundant clinical evidence suggest that administering PPARγ agonists, particularly thiazolidinedione (TZD) and a subgroup of angiotensin type 1-receptor blockers (ARBs), may be beneficial for patients with hypertension [25,27]. The gene discussed is PPARG; the disease is hypertensive disorder.